The Week in Review: Deals and Products
October 02, 2010 at 12:38 PM EDT
CCB’s $400 million China health care fund may invest in ex-China biopharmas; Tongjitang Chinese Medicines will sell off three divisions as it prepares to go private; Roche is making its cancer treatment Avastin in China; Bayer Schering announced the China launch of Betaferon® for multiple sclerosis; and RHEI Pharma amended its China marketing agreement with Access Pharma for MuGard™, an oral mucositis treatment. More details…. Stock Symbols: (NYSE: TCM) (VX: ROG) (XETRA: BAY) (OTCBB: ACCP)